Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics

Study Overview
=================
Brief Summary
-----------------
The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Detailed Description
-----------------
Cardiovascular and cerebrovascular diseases refer to ischemic and hemorrhagic diseases of the heart, brain and body tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. It is one of the major public health problems in the world. The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Official Title
-----------------
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study

Conditions
-----------------
Coronary Artery Disease, Arrhythmias, Cardiac, Heart Valve Diseases, Aortic Dissection, Heart Neoplasms, Myocarditis, Hypertension, Cardiomyopathies, Structural Heart Disease, Ischemic Cerebrovascular Disease, Hemorrhagic Cerebrovascular Disease, Brain Neoplasms

Intervention / Treatment
-----------------
* Other: Observational; No Interventions were given.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are regularly visited and followed up in the appropriate patient; department. All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases: coronary artery disease group; arrhythmia group; heart valve disease group; aortic dissection group; cardiac masses group; myocarditis group; hypertension group; cardiomyopathy group; structural heart disease group; ischemic cerebrovascular disease group; hemorrhagic cerebrovascular disease group; intracranial space occupying lesion group. Exclusion Criteria: Age <3 years or >80 years old; Pregnant and lactating women; The patient declined to provide informed consent to participate in the study; None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Coronary artery disease group<br>Diagnosis of coronary artery disease by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Arrhythmia group<br>Diagnosis of arrhythmia by clinical guidelines. by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Heart valve disease group<br>Diagnosis of heart valve disease by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| aortic dissection group<br>Diagnosis of aortic dissection by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Cardiac masses group<br>Diagnosis of cardiac messes by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Myocarditis group<br>Diagnosis of myocarditis by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Hypertension group<br>Diagnosis of hypertension by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Cardiomyopathy group<br>Diagnosis of cardiomyopathy by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Structural heart disease group<br>Diagnosis of structural heart disease by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Ischemic cerebrovascular disease group<br>Diagnosis of ischemic cerebrovascular disease by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Hemorrhagic cerebrovascular disease group<br>Diagnosis of hemorrhagic cerebrovascular disease by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|
| Intracranial space occupying lesion group<br>Diagnosis of intracranial space occupying by clinical guidelines. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of MACCE | Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, coronary revascularization, and stroke. | Through study completion, up to 5 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of all-cause mortality | Incidence of patients' death from any cause. | Through study completion, up to 5 years. | 
| Incidence of myocardial infarction | Changes of serum myocardial zymogram level and ECG were used for diagnosing of myocardial infarction. | Through study completion, up to 5 years. | 
| Incidence of coronary revascularization. | Incidence of percutaneous coronary intervention or coronary artery bypass grafting. | Through study completion, up to 5 years. | 
| Incidence of stroke | Stroke were assessed by radiologist using CT scan or other imaging test. | Through study completion, up to 5 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular diseases, Cerebrovascular diseases, Prognosis, Multi-omics